Answers are grounded in this paper and cite their sources.
Introduction: Sparsentan is a non-immunosuppressive dual endothelin angiotensin receptor antagonist (DEARA) indicated in the US to reduce proteinuria in adult and pediatric patients with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. We report long-term outcomes with sparsentan in pediatric patients with FSGS from 2 open-label extension (OLE) studies. Methods: In the phase 2 DUET (NCT01613118) study, patients were randomized to receive sparsentan or irbesartan for 8 weeks, after which they could receive sparsentan for up to 496 weeks in the OLE. In the phase 3 DUPLEX (NCT03493685) study, patients were randomized to receive sparsentan or irbesartan for 108 weeks, after which they could receive sparsentan for up to 156 weeks in the OLE. Post hoc analyses of pediatric patients (8 to < 18 years) assessed outcomes including changes in urine protein-to-creatinine ratio (UPCR), achievement of low proteinuria (including complete remission of proteinuria [CR]; UPCR of < 0.3 g/g), changes in eGFR, kidney failure, and safety. Results: Among 18 pediatric patients who entered the DUET OLE, rapid proteinuria reductions were observed at week 8 and largely maintained for ≈9 years (median change from baseline, −62.3% at week 456). CR was achieved by 44% of patients, and 11% had kidney failure. Among 23 pediatric patients who entered the DUPLEX OLE, reductions in proteinuria were sustained over ≈3 years, with a median change from baseline of −68.2% at week 156. CR was achieved by 22% of patients, and 9% had kidney failure. In both OLEs, few treatment-related adverse events were serious or led to treatment discontinuation. Conclusion: Pediatric patients with FSGS who received sparsentan in 2 OLE studies experienced clinically meaningful, durable reductions in proteinuria and low rates of kidney failure. The safety profile of sparsentan was consistent with previous observations. Results support the long-term tolerability and benefit of sparsentan in pediatric FSGS.
No takes yet. Share an insight, caveat, or question.
Lieberman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: